BioSpace News Archive

QuVa Pharma, Inc., a leading national 503B outsourcing services company to U.S. hospitals, will host a discussion at the 4th annual Wall Street Journal Health Forum on Tuesday, March 23, 2021

Elucid, a medical technology company developing AI software to enable cardiovascular disease detection, and researchers at the Karolinska Institutet (Stockholm, Sweden), led by Dr. Ulf Hedin, announced today the publication of new clinical data in the American Heart Association journal, Arteriosclerosis, Thrombosis, and Vascular Biology.

Urology of San Antonio, has enrolled their first patient in the VESAIR Clinical Trial. The VESAIR Clinical Trial is being conducted in several distinguished clinics throughout the US to test the safety and efficacy of the Vesair Bladder Control Balloon procedure

Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the Philippines has secured 7 million additional doses of COVID-19 Vaccine Moderna through a new supply agreement, bringing its confirmed order commitment up to 20 million doses.

We invite our shareholders and all interested parties to explore biotech small cap investment opportunities through two days of networking, dealmaking and discovery.

NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today announced the company has awarded a Technology Access Program grant with Illumina Accelerator startup, Doloromics, focused on gaining a deeper understanding of chronic pain diseases by spatially characterizing the dorsal root ganglion (DRG)

Eucure Biopharma, a subsidiary of Biocytogen focused on developing proprietary immuno-oncology antibodies, announced that its anti-CTLA-4 antibody (YH001), in combination with Junshi Biosciences’ anti-PD-1 monoclonal antibody,

ProMIS Neurosciences Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, is pleased to announce today the completion of an US$7M (CDN$8.75M) private placement of convertible unsecured debentures (the " Debentures ").

Scripps Health, has enrolled their first patient in the VESAIR Clinical Trial. The VESAIR Clinical Trial is being conducted in several distinguished clinics throughout the US to test the safety and efficacy of the Vesair Bladder Control Balloon procedure.

Marks vaccine’s first approval by an European Union member state, following Mexico , Pakistan and China Continues to boost production capacity to meet increasing demand Safe, stable storage and transportation between 2°C and 8°C, accessible by under-developed regions 95.47% effective overall in preventing severe COVID-19 diseases 14 days after vaccination